| __timestamp | Bio-Techne Corporation | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 9136000 |
| Thursday, January 1, 2015 | 144969000 | 5807000 |
| Friday, January 1, 2016 | 162364000 | 5571000 |
| Sunday, January 1, 2017 | 188462000 | 5366000 |
| Monday, January 1, 2018 | 210850000 | 6337000 |
| Tuesday, January 1, 2019 | 240515000 | 11347000 |
| Wednesday, January 1, 2020 | 255497000 | 30419000 |
| Friday, January 1, 2021 | 298182000 | 62176000 |
| Saturday, January 1, 2022 | 349103000 | 52827000 |
| Sunday, January 1, 2023 | 366887000 | 35049000 |
| Monday, January 1, 2024 | 389335000 |
Cracking the code
In the ever-evolving biotech industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Bio-Techne Corporation and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Bio-Techne has consistently demonstrated a robust growth trajectory, with its cost of revenue increasing by approximately 266% over the decade. In contrast, Ligand Pharmaceuticals has shown a more modest increase of around 283% until 2022, with data for 2023 not available.
Bio-Techne's strategic investments and operational efficiencies have allowed it to maintain a competitive edge, while Ligand's fluctuating costs reflect its adaptive strategies in a dynamic market. The data highlights the importance of cost management in sustaining growth and profitability in the biotech sector. As the industry continues to innovate, understanding these financial dynamics will be crucial for stakeholders and investors alike.
Cost Insights: Breaking Down Eli Lilly and Company and Bio-Techne Corporation's Expenses
Comparing Cost of Revenue Efficiency: AbbVie Inc. vs Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Merck & Co., Inc. and Bio-Techne Corporation's Expenses
Cost of Revenue: Key Insights for GSK plc and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Bio-Techne Corporation vs Grifols, S.A.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Bausch Health Companies Inc.
Comparing Innovation Spending: Bio-Techne Corporation and Ligand Pharmaceuticals Incorporated
BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and Travere Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Ligand Pharmaceuticals Incorporated and BioCryst Pharmaceuticals, Inc.